Form 4: Immuneering Corp Executive Granted Stock Options

Mallory Morales, Chief Accounting Officer of Immuneering Corp, was granted stock options for 110,000 shares on February 5, 2025.

Summary

• Mallory Morales, the Chief Accounting Officer of Immuneering Corp, received stock options.
• The transaction occurred on February 5, 2025.
• The stock options are for 110,000 shares of Class A Common Stock.
• The exercise price of the options is $1.91 per share.
• The options vest in equal monthly installments over four years, starting February 1, 2025, and will be fully vested by January 1, 2029.
• The options expire on February 5, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives.
• The vesting schedule and exercise price are typical for such grants, aiming to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates